North Wales, PA, United States of America

Shawn DeFrees

This inventor holds 61 USPTO granted patents and 34 published patent applications and 20 EPO patents, primarily in Glycosylation Techniques (CPC class A61K). Top assignees: Novo Nordisk A/s, Neose Technologies, Inc., Biogenerix Ag. Active years: 2005-2020.

USPTO Granted Patents = 61 (Patent Applications = 34)

% Patents Active = 37.7

EPO Patents = 20 (Patent Applications = 13)

Average Co-Inventor Count = 2.6

ph-index = 26

Forward Citations = 1,566(Granted Patents)

Forward Citations (Not Self Cited) = 637(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Neose Technologies, Inc.

Seneb Biosciences, Inc.

Abaron Biosciences, Inc.

patents

7. 1 out of 42

La Jolla Pharmaceutical Company

patents

Years Active: 2005-2020

Loading Chart...

Areas of Expertise:

Glycopegylation

FGF-21

Glycosylation

Therapeutic Proteins

Glycolipids

Polypeptide Conjugates

Antibody Toxin Conjugates

Nucleotide Sugars

Granulocyte Colony Stimulating Factor

Erythropoietin

Factor VIII

Synthetic Gangliosides

61 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10874714 - Method of treating fibroblast growth factor 21 (FGF-21) deficiency (2020-12-29),

2. 10555959 - Glycolipids as treatment for disease (2020-02-11),

3. 9493499 - Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography (2016-11-15),

4. 9200049 - Remodeling and glycopegylation of fibroblast growth factor (FGF) (2015-12-01),

5. 9187546 - Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants (2015-11-17),

6. 9187532 - Glycosylation of peptides via O-linked glycosylation sequences (2015-11-17),

7. 9150848 - Conjugated factor VIII molecules (2015-10-06),

8. 9068208 - Mutant endoglycoceramidases with enhanced synthetic activity (2015-06-30),

9. 9029331 - Glycopegylated granulocyte colony stimulating factor (2015-05-12),

10. 9005625 - Antibody toxin conjugates (2015-04-14),

11. 8969532 - Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography (2015-03-03),

12. 8916360 - Glycopegylated erythropoietin (2014-12-23),

13. 8911967 - One pot desialylation and glycopegylation of therapeutic peptides (2014-12-16),

14. 8853161 - Glycopegylation methods and proteins/peptides produced by the methods (2014-10-07),

15. 8841439 - Nucleotide sugar purification using membranes (2014-09-23),

Title: Innovations and Achievements of Shawn DeFrees

Introduction

Shawn DeFrees, a prominent inventor located in North Wales, PA, has made significant contributions to the field of biotechnology, with an impressive portfolio of 61 patents. His work focuses on innovative methods for treating various disorders, highlighting his dedication to advancing medical science and improving patient outcomes.

Latest Patents

Among Shawn's latest patents is a groundbreaking invention titled "Method of treating fibroblast growth factor 21 (FGF-21) deficiency." This invention pertains to mutants of Fibroblast Growth Factor (FGF), specifically FGF-20 and FGF-21, which are engineered to contain newly introduced N-linked or O-linked glycosylation sites. The patent includes polynucleotide coding sequences for the mutants, expression cassettes, and methods for producing the mutants, along with pharmaceutical compositions and applications for their use.

Another notable invention is related to "Glycolipids as treatment for disease." This patent encompasses compounds, compositions, and methods aimed at treating various disorders, including cancer, hyperinsulinemia, and atypical Parkinson's disease, among others. Each invention underscores DeFrees' commitment to addressing complex health challenges.

Career Highlights

Shawn DeFrees has collaborated with leading companies in the biotechnology sector, including Novo Nordisk A/S and Neose Technologies, Inc. His work at these institutions has allowed him to explore innovative solutions in genetics and disease treatment, ensuring that his inventions have practical applications in the medical field.

Collaborations

Throughout his career, DeFrees has worked alongside notable professionals such as David A. Zopf and Caryn Bowe. These collaborations have enriched his research and development efforts, contributing to the successful filing and granting of numerous patents that push the boundaries of current medical practices.

Conclusion

Shawn DeFrees continues to be a trailblazer in the field of biotechnology, with his extensive patent portfolio reflecting his inventive spirit and commitment to advancing healthcare solutions. His work not only showcases the impact of innovation in medicine but also inspires future inventors and researchers in their pursuit of technological advancements.